Linked Life Data

6635448

Source:http://linkedlifedata.com/resource/pubmed/id/6635448

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1983-12-17
pubmed:abstractText
The pharmacokinetic and microbiologic properties of rifampin are such that the antibiotic appears suitable for the treatment of urinary tract infections. However, its use alone for this indication is associated with an unacceptably high rate (approximately 30%) of acquisition of high-level resistance during therapy-an event that results in the failure of treatment. The combination of rifampin with another suitable antibiotic prevents this emergence of resistance. In vitro, pharmacokinetic, epidemiologic, and clinical studies with a combination of rifampin and trimethoprim (300 mg of rifampin: 80 mg of trimethoprim) both in England and in other countries have shown that this combination is effective and safe for the treatment of recurrent urinary tract infections. Provided that careful laboratory controls are used, the combination of rifampin and trimethoprim is a useful addition to the list of antibiotics available for the treatment of this condition.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0162-0886
pubmed:author
pubmed:issnType
Print
pubmed:volume
5 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S573-82
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Use of rifampin for the treatment of urinary tract infections.
pubmed:publicationType
Journal Article